Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Wegovy Maker Novo Nordisk Says New Pill Shows 14% Reduction in Heart Attacks, Strokes in Diabetic Patients
The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial.
Novo Nordisk's new pill shows 14% reduction in heart attacks in diabetics
The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial.
The pill form of Ozempic can reduce the risk of heart attacks and strokes, study says
The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and other cardiovascular events in a late-stage clinical trial.
Oral version of Novo diabetes drug protects heart health in large study
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.
Novo Nordisk's GLP-1 pill reduces cardiovascular events by 14%
Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study. The drug, Rybelsus, helped reduce the risk of these events,
23h
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...
FiercePharma
22h
Novo plots US, EU approval filings after oral semaglutide shows cardio benefits in certain diabetes patients
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
1h
Novo Nordisk plans label expansion for Rybelsus following Phase III win
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.
BioSpace
21h
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
9d
8 Reasons You May Still Be Hungry on Semaglutide
Semaglutide — the active ingredient in Ozempic®, Wegovy®, and Rybelsus® — can reduce your appetite and curb food cravings to ...
13d
Compounded Semaglutide: Is It Safe and Effective?
Compounded semaglutide is semaglutide with an altered formula to create an unbranded alternative to Wegovy and Ozempic.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback